

Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-May-2018
 Document Type: USP Monographs
 DocId: GUID-AA8E2EB2-A787-4AA4-BC7B-3EBD59E2ED43_3_en-US
 DOI: https://doi.org/10.31003/USPNF_M14107_03_01
 DOI Ref: er6k3

© 2025 USPC
 Do not distribute

Cefoxitin for Injection

DEFINITION

Cefoxitin for Injection contains Cefoxitin Sodium equivalent to NLT 90.0% and NMT 120.0% of the labeled amount of cefoxitin ($C_{16}H_{17}N_3O_7S_2$).

ASSAY

• PROCEDURE

Buffer: Dissolve 1.0 g of monobasic potassium phosphate and 1.8 g of dibasic sodium phosphate in 900 mL of water. Adjust with phosphoric acid or 10 N sodium hydroxide to a pH of 7.1 ± 0.1 , and dilute with water to 1 L. Pass through a membrane filter of 1- μ m or finer pore size.

Mobile phase: Acetonitrile, water, and glacial acetic acid (160:840:10). Pass through a membrane filter of 1- μ m or finer pore size.

Standard solution: 0.3 mg/mL of [USP Cefoxitin RS](#) in *Buffer*. Sonicate, if necessary, to dissolve. Use this solution within 5 h.

Sample solution 1 (where it is represented as being in a single-dose container): Nominally 0.3 mg/mL of cefoxitin prepared as follows. Constitute Cefoxitin for Injection in a volume of water corresponding to the volume of solvent specified in the labeling. Withdraw all of the withdrawable contents, using a suitable hypodermic needle and syringe, transfer to a suitable volumetric flask, and dilute with water to volume. Use this solution within 5 h.

Sample solution 2 (where the label states the quantity of cefoxitin in a given volume of constituted solution): Nominally 0.3 mg/mL of cefoxitin prepared as follows. Constitute Cefoxitin for Injection in a volume of water corresponding to the volume of solvent specified in the labeling. Transfer a suitable aliquot of the constituted solution to a suitable volumetric flask, and dilute with water to volume. Use this solution within 5 h.

Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

Mode: LC

Detector: UV 254 nm

Column: 3.9-mm $\times$ 30-cm; 5- to 10- μ m packing L1

Flow rate: 1 mL/min

Injection volume: 10 μ L

System suitability

Sample: *Standard solution*

Suitability requirements

Column efficiency: NLT 2800 theoretical plates

Tailing factor: NMT 1.5

Relative standard deviation: NMT 1.0%

Analysis

Samples: *Sample solution 1* or *Sample solution 2* and *Standard solution*

Calculate the percentage of the labeled amount of cefoxitin ($C_{16}H_{17}N_3O_7S_2$) in the portion of Cefoxitin for Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times P \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of the *Standard solution* (mg/mL)

C_U = nominal concentration of cefoxitin in *Sample solution 1* or *Sample solution 2* (mg/mL)

P = potency of cefoxitin in [USP Cefoxitin RS](#) (mg/mg)

Acceptance criteria: 90.0%–120.0%

PERFORMANCE TESTS

• [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meets the requirements

SPECIFIC TESTS

- **CONSTITUTED SOLUTION:** At the time of use, it meets the requirements in [Injections and Implanted Drug Products \(1\)](#), [Specific Tests, Completeness and clarity of solutions](#).
- **BACTERIAL ENDOTOXINS TEST (85):** NMT 0.13 USP Endotoxin Unit/mg of cefoxitin
- **STERILITY TESTS (71):** It meets the requirements when tested as directed in [Test for Sterility of the Product to Be Examined, Membrane Filtration](#).
- **PARTICULATE MATTER IN INJECTIONS (788):** It meets the requirements for small-volume injections.
- **pH (791).**

Sample solution: 100 mg/mL

Acceptance criteria: 4.2–7.0

- **WATER DETERMINATION, Method I (921).**

Analysis: Use a mixture of ethylene glycol and pyridine (3:1) in the titration vessel in place of methanol.

Acceptance criteria: NMT 1.0%

- **OTHER REQUIREMENTS:** It meets the requirements of the *Identification* tests in [Cefoxitin Sodium](#). It meets the requirements in [Labeling \(7\)](#), [Labels and Labeling for Injectable Products](#).

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve as described in [Packaging and Storage Requirements \(659\)](#), [Injection Packaging, Packaging for constitution](#).
- **USP REFERENCE STANDARDS (11).**
[USP Cefoxitin RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
CEFOXITIN FOR INJECTION	Documentary Standards Support	SM12020 Small Molecules 1

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 49(1)

Current DocID: GUID-AA8E2EB2-A787-4AA4-BC7B-3EBD59E2ED43_3_en-US

Previous DocID: GUID-AA8E2EB2-A787-4AA4-BC7B-3EBD59E2ED43_1_en-US

DOI: https://doi.org/10.31003/USPNF_M14107_03_01

DOI ref: [er6k3](#)

OFFICIAL